DETAILED INVESTIGATION OF THE DIAGNOSTIC-VALUE IN TUMOR HISTOPATHOLOGY OF ICR.2, A NEW MONOCLONAL-ANTIBODY TO EPITHELIAL MEMBRANE ANTIGEN

The production and detailed immunostaining properties of a new rat monoclonal antibody (ICR.2) to epithelial membrane antigen are reported. The antibody was selected for its ability to compete with the polyclonal antiserum (M7), used in the original immunohistological studies, in order that it might serve as a direct replacement in diagnosing epithelial tumours. Most of the staining reactions on normal tissues were identical to those previously reported with M7 but there were some important differences. They included: positivity of renal and adrenal capsular fibroblasts, perineurium, some myoepithelial and smooth muscle cells, occasional osteoblasts and squamous and thyroid follicular epithelum in the normal state. The intercellular canaliculi of sweat glands and secretory canaliculi of gastric oxyntic cells were clearly demonstrated. These staining reactions could be obtained with M7 when a sensitive detection system was used although the results were usually weak and inconsistent. Nearly all adeno‐, squamous and transitional carcinomas were positive. The remaining tumours fell into three major groups: (1) those which were consistently or nearly consistently negative–melanoma, seminoma, rhabdomyosarcoma, alveolar soft part sarcoma, adrenal cortical carcinoma, granulocytic sarcoma, paraganglioma, non‐Hodgkin's lymphoma, Hodgkin's disease and embryonal carcinoma; (2) those which were either negative or positive with distinctive patterns of staining–basal cell carcinoma, embryonal tumours: and (3) non‐epithelial tumours that were consistently positive–epithelioid sarcoma, synovial sarcoma, osteosarcoma, chordoma and myeloma–or positive in a significant minority of cases–leiomyosarcoma, malignant fibrous histiocytoma, clear cell sarcoma of tendon sheath, various neuroectodermal tumours. It is concluded that ICR.2 is a useful reagent for distinguishing carcinoma from tumours in the first two groups, particularly if used in combination with other antibodies, but has no or limited use in excluding tumours belonging to group 3. Copyright © 1990, Wiley Blackwell. All rights reserved